According to multivariate analysis, post-procedural significant early increase (≥0.3 mg/dL or ≥10%) in cystatin C developed in 231 patients (22.2%), was not independent predictor of CI-AKI (adjusted OR: 1.23, 95% CI, 0.56–2.69, P = 0.612), and long-term mortality (adjusted HR: 0.90; P = 0.838). The gene discussed is CST3; the disease is acute kidney injury.